Statin use was associated with a 58% decreased risk of venous thromboembolism (OR 0.42; 95% CI 0.23-0.76; P=0.002), whereas fibrates and thienopyridines were not associated with a reduced risk.
Case-Control (n=754)
No
Does statin use reduce the risk of venous thromboembolic events compared to non-use?
Statin use, but not fibrates or thienopyridines, is associated with a significantly reduced risk of venous thromboembolism.
Effect estimate: OR 0.42 (95% CI 0.23-0.76)
p-value: p=0.002
Previous studies of selected patients have suggested a reduction in the risk of venous thromboembolism with the use of statins. The objective of this study is to evaluate the influence of statin use on the risk of venous thromboembolic (VTE) events. The study is a case-control study (EDITH: Etude des Déterminants et Interactions de la Thrombose Veineuse), designed to investigate the genetic and environmental risk factors of VTE. A total of 377 patients consecutively hospitalized in the Brest University Hospital for a documented VTE event, between May 2000 and May 2002, and 377 age- and sex-matched controls were studied. Statin use was associated with a 58% decreased risk of VTE odds ratio (OR) 0.42; 95% confidence interval (CI) 0.23-0.76; P = 0.002. Adjustment for age, gender, coronary heart disease, atherosclerothrombotic disease or current use of aspirin did not alter the result. Neither fibrates (OR 1.38; 95% CI 0.76-2.52; P = 0.26), nor thienopyridines (OR 1.07; 95% CI 0.48-2.41; P = 0.85) were associated with a reduced risk of VTE. Aspirin use tended to decrease the risk of VTE, but this result was not significant (OR, 0.66; 95% CI, 0.42-1.05). The use of statins is associated with a significant reduction in the risk of VTE, irrespective of age, gender, and past history of atherosclerothrombotic disease, as well as the use of aspirin. This possible protective effect of statins warrants further investigations.
Lacut et al. (Fri,) conducted a case-control in Venous thromboembolism (n=754). Statins vs. Controls (non-use) was evaluated on Risk of venous thromboembolic (VTE) events (OR 0.42, 95% CI 0.23-0.76, p=0.002). Statin use was associated with a 58% decreased risk of venous thromboembolism (OR 0.42; 95% CI 0.23-0.76; P=0.002), whereas fibrates and thienopyridines were not associated with a reduced risk.